Cellectis annonce sa participation à plusieurs conférences investisseurs
Filed with Euronext · · 2 pages · French and English
Watch Cellectis' latest callCellectis (Euronext:ALCLS) Q1 2026 Earnings Call · Replay · May 11Read the transcript of Cellectis (Euronext:ALCLS) Q1 2026 Earnings CallEarlier from Cellectis
- Cellectis Reports Financial Results for the Second Quarter 2026
- Cellectis to Report Second Quarter Financial Results on August 6, 2026
- Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
- Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
- Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Later from Cellectis
- Cellectis Announces Participation in Upcoming Investor Conferences
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
- Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
- Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Follow Cellectis into a list and get an email when it puts out news.
Follow Cellectis